Overview Dividends

(CLX) The Clorox - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1890541097

Disinfectants, Bleach, Litter, Dressings, Filtration

CLX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -5.04%
EPS Trend (3Y Correlation): 23.1%

CLX Revenue

Revenue Growth (3Y CAGR): -6.42%
Revenue Trend (3Y Correlation): -23.9%

Risk via 10d forecast
Volatility	22.1%
Value at Risk 5%th	35.7%
Relative Tail Risk	-1.48%

Reward TTM
Sharpe Ratio	-2.03
Alpha	-40.91

Character TTM
Hurst Exponent	0.444
Beta	0.204
Beta Downside	0.214

Drawdowns 3y
Max DD	36.63%
Mean DD	13.62%
Median DD	12.53%

Description: CLX The Clorox October 30, 2025

The Clorox Company (NYSE: CLX) manufactures and markets a broad portfolio of consumer and professional products across four segments: Health & Wellness (cleaning, disinfecting, bleach, and professional food-service items), Household (cat litter, Glad bags, Kingsford grilling supplies), Lifestyle (Hidden Valley dressings, Brita water-filtration, Burt’s Bees personal-care) and International (a mix of the same brands plus vitamins and supplements). Its products reach shoppers via mass retailers, grocery chains, warehouse clubs, dollar stores, hardware outlets, drug and pet stores, military channels, third-party and owned e-commerce sites, and a direct sales force.

In FY 2023 Clorox generated roughly $7.8 billion in net sales, with an operating margin of about 15 % and a dividend yield near 2.5 %. The Health & Wellness segment contributed the largest share of revenue, driven by sustained demand for disinfecting solutions post-COVID-19, while the Lifestyle segment showed double-digit growth from premium-priced natural personal-care and water-filtration products.

Key economic drivers for CLX include inflationary pressure on raw-material costs (e.g., sodium hypochlorite and plastics), modest pricing power in the defensive household-products sector, and a consumer shift toward sustainable and “green” brands-trends that have historically supported modest revenue resilience. For a deeper quantitative assessment, you may find the ValueRay platform’s sector-adjusted valuation models useful.

CLX Stock Overview

Market Cap in USD	13,096m
Sub-Industry	Household Products
IPO / Inception	1983-03-21
Return 12m vs S&P 500	-43.4%
Analyst Rating	3.05 of 5

CLX Dividends

Dividend Yield	4.75%
Yield on Cost 5y	2.77%
Yield CAGR 5y	2.76%
Payout Consistency	64.2%
Payout Ratio	73.3%

CLX Growth Ratios

CAGR 3y	-7.92%
CAGR/Max DD Calmar Ratio	-0.22
CAGR/Mean DD Pain Ratio	-0.58
Current Volume	1690.4k
Average Volume	1843.2k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (791.0m TTM) > 0 and > 6% of Revenue (6% = 406.3m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA -0.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -7.96% (prev -0.04%; Δ -7.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 853.0m > Net Income 791.0m (YES >=105%, WARN >=100%)

Net Debt (2.91b) to EBITDA (1.45b) ratio: 2.01 <= 3.0 (WARN <= 3.5)

Current Ratio 0.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (123.0m) change vs 12m ago -1.33% (target <= -2.0% for YES)

Gross Margin 44.34% (prev 44.42%; Δ -0.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 122.8% (prev 135.9%; Δ -13.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 11.90 (EBITDA TTM 1.45b / Interest Expense TTM 93.0m) >= 6 (WARN >= 3)

Altman Z'' 0.86

(A) -0.10 = (Total Current Assets 1.70b - Total Current Liabilities 2.23b) / Total Assets 5.53b

(B) 0.04 = Retained Earnings (Balance) 200.0m / Total Assets 5.53b

(D) 0.03 = Book Value of Equity 166.0m / Total Liabilities 5.39b

Total Rating: 0.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.67

1. Piotroski 5.50pt = 0.50

2. FCF Yield 3.97% = 1.99

3. FCF Margin 9.39% = 2.35

4. Debt/Equity data missing

5. Debt/Ebitda 2.01 = -0.03

6. ROIC - WACC (= 26.19)% = 12.50

7. RoE data missing

8. Rev. Trend -23.86% = -1.79

9. EPS Trend 23.08% = 1.15

What is the price of CLX shares?

As of November 16, 2025, the stock is trading at USD 103.68 with a total of 1,690,400 shares traded.
Over the past week, the price has changed by -3.43%, over one month by -12.21%, over three months by -13.83% and over the past year by -35.10%.

Is The Clorox a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, The Clorox (NYSE:CLX) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 66.67 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLX is around 91.28 USD . This means that CLX is currently overvalued and has a potential downside of -11.96%.

Is CLX a buy, sell or hold?

The Clorox has received a consensus analysts rating of 3.05. Therefor, it is recommend to hold CLX.

Strong Buy: 2
Buy: 2
Hold: 13
Sell: 3
Strong Sell: 1

What are the forecasts/targets for the CLX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	124.8	20.3%
Analysts Target Price	124.8	20.3%
ValueRay Target Price	99.1	-4.4%

CLX Fundamental Data Overview November 10, 2025

Market Cap USD = 13.10b (13.10b USD * 1.0 USD.USD)
P/E Trailing = 16.854
P/E Forward = 19.6464
P/S = 1.9341
P/B = 46.5805
P/EG = 3.4454
Beta = 0.565
Revenue TTM = 6.77b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 2.48b USD (from longTermDebt, last fiscal year)
Short Term Debt = 307.0m USD (from shortTermDebt, last quarter)
Debt = 3.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.91b USD (from netDebt column, last quarter)
Enterprise Value = 16.01b USD (13.10b + Debt 3.08b - CCE 166.0m)
Interest Coverage Ratio = 11.90 (Ebit TTM 1.11b / Interest Expense TTM 93.0m)
FCF Yield = 3.97% (FCF TTM 636.0m / Enterprise Value 16.01b)
FCF Margin = 9.39% (FCF TTM 636.0m / Revenue TTM 6.77b)
Net Margin = 11.68% (Net Income TTM 791.0m / Revenue TTM 6.77b)
Gross Margin = 44.34% ((Revenue TTM 6.77b - Cost of Revenue TTM 3.77b) / Revenue TTM)
Gross Margin QoQ = 41.71% (prev 46.48%)
Tobins Q-Ratio = 2.90 (Enterprise Value 16.01b / Total Assets 5.53b)
Interest Expense / Debt = 0.84% (Interest Expense 26.0m / Debt 3.08b)
Taxrate = 23.36% (25.0m / 107.0m)
NOPAT = 848.4m (EBIT 1.11b * (1 - 23.36%))
Current Ratio = 0.76 (Total Current Assets 1.70b / Total Current Liabilities 2.23b)
Debt / Equity = -139.9 (out of range, set to none) (Debt 3.08b / totalStockholderEquity, last quarter -22.0m)
Debt / EBITDA = 2.01 (Net Debt 2.91b / EBITDA 1.45b)
Debt / FCF = 4.58 (Net Debt 2.91b / FCF TTM 636.0m)
Total Stockholder Equity = 71.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.31% (Net Income 791.0m / Total Assets 5.53b)
RoE = 1110 % (out of range, set to none) (Net Income TTM 791.0m / Total Stockholder Equity 71.2m)
RoCE = 43.32% (EBIT 1.11b / Capital Employed (Equity 71.2m + L.T.Debt 2.48b))
RoIC = 31.80% (NOPAT 848.4m / Invested Capital 2.67b)
WACC = 5.60% (E(13.10b)/V(16.17b) * Re(6.77%) + D(3.08b)/V(16.17b) * Rd(0.84%) * (1-Tc(0.23)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.64%
[DCF Debug] Terminal Value 79.37% ; FCFE base≈649.2m ; Y1≈701.2m ; Y5≈867.8m
Fair Price DCF = 124.1 (DCF Value 15.14b / Shares Outstanding 122.0m; 5y FCF grow 9.04% → 3.0% )
EPS Correlation: 23.08 | EPS CAGR: -5.04% | SUE: 0.20 | # QB: 0
Revenue Correlation: -23.86 | Revenue CAGR: -6.42% | SUE: 0.35 | # QB: 0

Additional Sources for CLX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle